# Medicines and Healthcare products Regulatory Agency

## MANUFACTURER'S AUTHORISATION

1: Authorisation Number UK MIA(IMP) 13581

**NOVA LABORATORIES LIMITED** 2: Name of authorisation holder

NOVA LABORATORIES LIMITED, MARTIN HOUSE / EDWIN HOUSE, GLOUCESTER CRESCENT, WIGSTON, LE18 4YL, 3: Address(es) of manufacturing site(s)

UNITED KINGDOM

NOVA LABORATORIES LIMITED, MARTIN HOUSE / EDWIN 4: Legally registered address of authorisation holder

HOUSE, GLOUCESTER CRESCENT, WIGSTON, LE18 4YL,

UNITED KINGDOM

Confidential

5: Scope of authorisation and dosage forms ANNEX 1 and/ or ANNEX 2

Part 6 of The Medicines for Human Use (Clinical Trials) 6: Legal Basis of authorisation

Regulations 2004 [SI 2004/1031]

7: Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation

8: Authorisation Date 15/03/2024

9: Annexes attached Annex 1 and/or Annex 2

#### SCOPE OF AUTHORISATION

#### Annex 2

Name and address of the site:

NOVA LABORATORIES LIMITED, MARTIN HOUSE / EDWIN HOUSE, GLOUCESTER CRESCENT, WIGSTON, LE18 4YL, UNITED **KINGDOM** 

**Human Investigational Medicinal Products** 

**Authorised Operations** 

MANUFACTURING OPERATIONS (according to part 1)

# Part 1 - MANUFACTURING OPERATIONS

### [ 1.1 ] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.4] Small volume liquids

[1.1.1.5] Solids and implants

[ 1.1.1.6 ] Other aseptically prepared products

Dry Powders. Spray dried powder.

[ 1.2 ] Non-sterile investigational medicinal products

Issue Date: 15 Mar 2024

[ 1.2.1 ] Non-Sterile Products (processing operations for the following dosage forms) [1.2.1.1] Capsules, hard shell [ 1.2.1.6 ] Liquids for internal use [ 1.3 ] Biological investigational medicinal products [1.3.1] Biological medicinal products [ 1.3.1.2 ] Immunological products [1.3.1.3] Cell therapy products [1.3.1.4] Gene therapy products [ 1.3.1.5 ] Biotechnology products [ 1.3.1.6 ] Human or animal extracted products [ 1.4 ] Other investigational medicinal products or manufacturing activitiy [ 1.4.2 ] Sterilisation of active substances/excipients/finished products: [ 1.4.2.1 ] Filtration [ 1.5 ] Packaging [1.5.1] Primary packaging [1.5.1.1] Capsules, hard shell [ 1.5.1.6 ] Liquids for internal use [ 1.5.1.11 ] Semi-solids [1.5.2] Secondary packaging [ 1.6 ] Quality control testing [ 1.6.1 ] Microbiological: sterility [ 1.6.2 ] Microbiological: non-sterility [1.6.3] Chemical/Physical



Page 2 of 2 Issue Date: 15 Mar 2024

[1.6.4] Biological